World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
76
Citations
19510
World Ranking
1921
National Ranking
939

Hideho Okada publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Hideho Okada sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 314 publications — 67th percentile

67% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Hideho Okada D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Hideho Okada sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 76 D-Index — 62nd percentile

62% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Hideho Okada is affiliated with the University of California, San Francisco in the United States. Their research portfolio primarily spans the fields of Medicine and Immunology and Microbiology, with significant contributions to the subfields of Oncology, Immunology, Genetics, Molecular Biology, and Biomedical Engineering.

Their scholarly work concentrates on topics related to CAR-T cell therapy research, glioma diagnosis and treatment, immunotherapy and immune responses, cancer immunotherapy and biomarkers, immune cells in cancer, virus-based gene therapy research, and nanowire synthesis and applications.

Okada's frequent publication venues include Neuro-Oncology, Cancer Research, Regular and Young Investigator Award Abstracts, bioRxiv (Cold Spring Harbor Laboratory), and the Journal for ImmunoTherapy of Cancer.

Collaborative work features several frequent co-authors, such as Takahide Nejo, Akane Yamamichi, Payal Watchmaker, Marco Gallus, and Senthilnath Lakshmanachetty.

Their recent papers include:

  • SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma (2021, Science Translational Medicine)
  • RASA2 ablation in T cells boosts antigen sensitivity and long-term function (2022, Nature)
  • Discovering dominant tumor immune archetypes in a pan-cancer census (2021, Cell)
  • Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective (2024, Cell)
  • Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma (2020, Journal of Clinical Investigation)

Best Publications

  • A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

    Donald M. O’Rourke;MacLean P. Nasrallah;Arati Desai;Jan J. Melenhorst

  • Actively personalized vaccination trial for newly diagnosed glioblastoma

    Norbert Hilf;Sabrina Kuttruff-Coqui;Katrin Frenzel;Valesca Bukur

  • Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.

    Hideho Okada;Pawel Kalinski;Ryo Ueda;Aki Hoji

  • Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.

    Hideho Okada;Michael Weller;Raymond Huang;Gaetano Finocchiaro

  • Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment

    Sören Müller;Gary Kohanbash;S. John Liu;Beatriz Alvarado

  • Classification of current anticancer immunotherapies

    Lorenzo Galluzzi;Erika Vacchelli;José Manuel Bravo-San Pedro;Aitziber Buqué

  • Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma

    Laura A. Johnson;John Scholler;Takayuki Ohkuri;Akemi Kosaka

  • SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma

    Joseph H. Choe;Payal B. Watchmaker;Milos S. Simic;Ryan D. Gilbert

  • COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor Cells

    Mitsugu Fujita;Gary Kohanbash;Wendy Fellows-Mayle;Ronald L. Hamilton

  • Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas

    Gary Kohanbash;Diego A. Carrera;Shruti Shrivastav;Brian J. Ahn

  • Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models

    Xinmei Zhu;Fumihiko Nishimura;Kotaro Sasaki;Mitsugu Fujita

  • STING Contributes to Antiglioma Immunity via Triggering Type I IFN Signals in the Tumor Microenvironment

    Takayuki Ohkuri;Arundhati Ghosh;Akemi Kosaka;Jianzhong Zhu

  • RASA2 ablation in T cells boosts antigen sensitivity and long-term function

    Unknown

  • Antigen-Specific Immune Responses and Clinical Outcome After Vaccination With Glioma-Associated Antigen Peptides and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Children With Newly Diagnosed Malignant Brainstem and Nonbrainstem Gliomas

    Ian F. Pollack;Regina I. Jakacki;Lisa H. Butterfield;Ronald L. Hamilton

  • Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy

    Xinmei Zhu;Mitsugu Fujita;Linda A. Snyder;Hideho Okada

  • Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.

    Zinal S. Chheda;Gary Kohanbash;Gary Kohanbash;Kaori Okada;Naznin Jahan

  • GM-CSF Promotes the Immunosuppressive Activity of Glioma-Infiltrating Myeloid Cells through Interleukin-4 Receptor-α

    Gary Kohanbash;Kayla McKaveney;Masashi Sakaki;Ryo Ueda

  • Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1

    Ryo Ueda;Gary Kohanbash;Kotaro Sasaki;Mitsugu Fujita

  • EphA2 as a glioma-associated antigen: a novel target for glioma vaccines.

    Manabu Hatano;Junichi Eguchi;Tomohide Tatsumi;Naruo Kuwashima

  • Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity

    Tomohide Tatsumi;Jian Huang;William E. Gooding;Andrea Gambotto

  • Immunotherapeutic Approaches for Glioma

    Hideho Okada;Gary Kohanbash;Xinmei Zhu;Edward R. Kastenhuber

Frequent Co-Authors

Ian F. Pollack
Ian F. Pollack University of Pittsburgh
Walter J. Storkus
Walter J. Storkus University of Pittsburgh
Lisa H. Butterfield
Lisa H. Butterfield University of California, San Francisco
Ronald L. Hamilton
Ronald L. Hamilton University of Pittsburgh
Michael T. Lotze
Michael T. Lotze University of Pittsburgh
Pawel Kalinski
Pawel Kalinski Roswell Park Comprehensive Cancer Center
Carl H. June
Carl H. June University of Pennsylvania
Simon C. Watkins
Simon C. Watkins University of Pittsburgh
Theresa L. Whiteside
Theresa L. Whiteside University of Pittsburgh
Marcela V. Maus
Marcela V. Maus Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing related nursing degrees can expand career opportunities, especially in acute care and clinical research. Transitioning to an advanced role such as an Acute Care Nurse Practitioner is possible through specialized acnp programs, which prepare nurses to manage critically ill patients and work closely with immunology specialists.

Accelerated programs offer a fast track for those aiming to become nurse practitioners. Consider exploring a nurse practitioner accelerated program that combines rigorous coursework with clinical experience, enabling quicker entry into specialized healthcare roles associated with immunology.

For individuals without a nursing background, online pathways such as online absn programs for non nurses provide accessible routes to enter the nursing field and eventually specialize in immunology-related care.

Additionally, some may seek the easiest entry points via easiest accelerated nursing programs to get into. These programs can offer a practical starting point for building essential skills before moving into advanced immunology-focused roles.

Best Scientists Citing Hideho Okada

Trending Scientists

Recently Published Articles